Inside STAT: A women’s health firm sought backing for a much-needed drug. Men didn’t get it

THREE OF THE FOUR MEMBERS OF ANTIVA'S MANAGEMENT TEAM ARE WOMEN. (CHRISTIE HEMM KLOK FOR STAT)

Antiva Biosciences is working on a drug that aims to make surgery for cervical lesions caused by HPV — which about 500,00 U.S. women undergo each year — no longer necessary. But it’s been an uphill battle for the company to make its case to investors and doctors, particularly the men who dominate those fields. Male investors have been skeptical and male OB-GYNs have questioned the need for a drug, saying they think surgery is adequate. It’s a prime example of the challenges involved in selling a company centered around women’s health. But Antiva’s story also speaks to a rising effort to champion treatments for conditions that affect women. STAT’s Rebecca Robbins has the story here.